Showing 2061-2070 of 2192 results for "".
- Health Factors in 20s May Predict Cerebrovascular Disease and Dementia Later in Lifehttps://practicalneurology.com/news/health-factors-in-20s-may-predict-cerebrovascular-disease-and-dementia-later-in-life/2469168/Results from a preliminary study show that the presence of smoking, high cholesterol, or high body mass index (BMI) in a person's 20s may make them more likely to have cerebrovascular disease and dementia later in life. In the study, 189 people, mean age 24, were followed for 30 yea
- FDA Approves Expanded Indication for Vigabatrinhttps://practicalneurology.com/news/fda-approves-expanded-indication-for-vigabatrin/2469139/The Food and Drug Administration has approved expanded indications on the label for vigabatrin (Sabril, Lundbeck, Deerfield, IL) to treat refractory complex partial seizures in individuals age 2 to 10 years. This new label expansion now means there will be no age gap for individuals needing criti
- Sleep Deprivation May Increase Serum Tau Levelshttps://practicalneurology.com/news/sleep-deprivation-may-increase-serum-tau-levels/2469128/A preliminary study published in Neurology, has found that when young, healthy men were deprived of just 1 night of sleep, they had higher levels of tau in their blood than when they had a full, uninterrupted night of rest. In the study, participants had an average 17% increase in
- More Sites Offer Free Parkinson Disease Genetic Testing and Counselinghttps://practicalneurology.com/news/more-sites-offer-free-parkinson-disease-genetic-testing-and-counseling/2469122/The Parkinson's Foundation has added 5 new sites for PD GENEration: Mapping the Future of Parkinson's Disease, a first-of-its-kind national initiative that offers free genetic testing and counseling for clinically relevant Parkinson disease (PD)-related genes. The new sites include Massac
- Mixed Martial Artists and Boxers Show Different Effects From Head Injurieshttps://practicalneurology.com/news/mixed-martial-artists-and-boxers-show-different-effects-from-head-injuries/2469120/A new study shows different effects in the brain for younger current fighters compared with older, retired fighters. The study is published in the December 23, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology. Both the current and former fighters ha
- FDA Approves Lemborexant For Treatment of Insomnia in Adultshttps://practicalneurology.com/news/fda-approves-lemborexant-for-treatment-of-insomnia-in-adults/2469116/The Food and Drug Administration (FDA) approved lemborexant (Dayvigo, Eisai, Woodcliff Lake, NJ) for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. In clinical trials, participants age 18 years or more with insomnia treated with lemb
- Perampanel Treatment for Partial-Onset and Secondary Generalized Tonic-Clonic Seizures Provides Durable Reduction in Seizure Frequency in Phase 3 and Phase 4 Trialshttps://practicalneurology.com/news/perampanel-treatment-for-partial-onset-seizures-and-generalized-tonic-clonic-seizures-provides-durable-reduction-in-seizure-frequency-in-phase-3-and-phase-4-trials/2469105/In the FREEDOM study (NCT03201900), a phase 3 open-label study, perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) was used as monotherapy to treat study participants, age 12 years or more, who were newly diagnosed with partial-onset sei
- Nasal Midazolam Stops Repetitive Seizure Clusters and Can Be Self- or Caregiver-Administeredhttps://practicalneurology.com/news/nasal-midazolam-stops-repetitive-seizure-clusters-and-can-be-self-or-caregiver-administered/2469100/Midazolam nasal spray (Nayzilam; UCB, Atlanta, GA) was approved by the Food and Drug Administration (FDA) in May 2019 for acute treatment of intermittent stereotypic seizure activity (eg, seizure clusters and acute repetitive seizures) in individuals age 12 years or more. The nasal spray became a
- Gantenerumab Reduces Amyloid Levels in Open-Label Extension Studieshttps://practicalneurology.com/news/gantenerumab-reduces-amyloid-levels-in-open-label-extension-studies/2469093/Pharmacodynamic 3-year data from open-label extension studies of gantenerumab have shown that approximately 80% of participants have amyloid levels reduced to a point considered amyloid negative. In addition, approximately half of participants have amyloid levels that are as low as that seen in h
- Midazolam Nasal Spray for Acute Treatment of Seizure Clusters To Be Available In Decemberhttps://practicalneurology.com/news/midazolam-nasal-spray-for-acute-treatment-of-seizure-clusters-to-be-available-in-december/2469082/In December, midazolam nasal spray (Nayzilam; UCB, Atlanta, GA) will be available in retail pharmacies for acute treatment of intermittent, stereotypic seizure activity (eg, seizure clusters and acute repetitive seizures) in patients age 12 years or more with epilepsy. Midazolam i